100 Fifth Avenue
Waltham, MA 02451
United States
617 977 5700
https://www.apellis.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 702
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Cedric Francois M.D., Ph.D. | Co-Founder, President, CEO & Director | 1,44M | 35,28M | 1972 |
Mr. Mark Jeffrey Delong | Chief Business & Strategy Officer | N/D | N/D | 1977 |
Dr. Philip Ferrone M.D. | Chief Medical Retina Advisor | N/D | N/D | N/D |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
L'ISS Governance QualityScore di Apellis Pharmaceuticals, Inc. al 29 aprile 2024 è 5. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 5; diritti degli azionisti: 8; retribuzione: 4.